- Home
- BH vs GHRS Comparison
BH vs GHRS Comparison
Compare BH & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BH | GHRS |
|---|---|---|
| Founded | 1934 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BH | GHRS |
|---|---|---|
| Price | $311.10 | $14.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | 144.3K | ★ 194.6K |
| Earning Date | 05-08-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $597.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $195.05 | $7.98 |
| 52 Week High | $483.60 | $19.51 |
Technical Indicators
Market Signals| Indicator | BH | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 44.21 |
| Support Level | $301.27 | $13.75 |
| Resistance Level | $319.42 | $14.80 |
| Average True Range (ATR) | 17.79 | 0.79 |
| MACD | -0.61 | -0.10 |
| Stochastic Oscillator | 18.35 | 9.34 |
Price Performance
Historical ComparisonAbout BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.